Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04560322
Title Venetoclax-Obinutuzumab +/- Ibrut in R/R CLL
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

chronic lymphocytic leukemia

chronic lymphocytic leukemia/small lymphocytic lymphoma

Therapies

Obinutuzumab + Venetoclax

Ibrutinib + Obinutuzumab + Venetoclax

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.